{
  "company": "Exact Sciences",
  "ticker": "EXAS",
  "period": {
    "from": "2026-03-08",
    "to": "2026-04-07",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 33,
    "negative": 30,
    "neutral": 39
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Exact Sciences (EXAS) from 2026-03-08 to 2026-04-07. Analyzed 102 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "What to know about Cologuard Classic in Tucson on PGA Tour Champions",
      "date": "2026-03-16",
      "source": "news",
      "score": 0.778
    },
    {
      "title": "Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott",
      "date": "2026-03-11",
      "source": "news",
      "score": 0.727
    },
    {
      "title": "Digital Intervention (MiVacunaLA 2.0) to Promote COVID-19 Vaccine Acceptance Among Hispanic Children: Community-Based Randomized Controlled Trial.",
      "date": "2026 Mar 3",
      "source": "pubmed",
      "score": 0.681
    },
    {
      "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider",
      "date": "2026-03-10",
      "source": "news",
      "score": 0.66
    },
    {
      "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.637
    },
    {
      "title": "Global Point-of-Care Molecular Diagnostics Market Projected to Reach USD 13.05 Billion by 2035; Growth is Driven by Increasing Need for Fast Near-Patient Testing Globally – SNS Insider",
      "date": "2026-03-09",
      "source": "news",
      "score": 0.625
    },
    {
      "title": "REPORT: As a Public School Teacher, Texas Democrat James Talarico Had Students Write ‘Obama Memoirs’ and Encouraged Them to Watch the DNC",
      "date": "2026-03-13",
      "source": "news",
      "score": 0.612
    },
    {
      "title": "Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline Value",
      "date": "2026-03-12",
      "source": "news",
      "score": 0.612
    },
    {
      "title": "Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp.",
      "date": "2026-03-15",
      "source": "alpha_vantage",
      "score": 0.572
    },
    {
      "title": "Learning to breathe for radiation therapy: a scoping review of deep inspiration breath-hold training.",
      "date": "2026 Apr 2",
      "source": "pubmed",
      "score": 0.527
    }
  ],
  "top_negative": [
    {
      "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": -1.0
    },
    {
      "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.945
    },
    {
      "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
      "date": "2026-03-22",
      "source": "news",
      "score": -0.791
    },
    {
      "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.",
      "date": "2026-04-07",
      "source": "pubmed",
      "score": -0.791
    },
    {
      "title": "Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.758
    },
    {
      "title": "Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.",
      "date": "2026 Mar 1",
      "source": "pubmed",
      "score": -0.691
    },
    {
      "title": "Privia Health Screening Program Increases Colorectal Cancer Screening Rates",
      "date": "2026-03-14",
      "source": "alpha_vantage",
      "score": -0.66
    },
    {
      "title": "Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.",
      "date": "2026 Apr 4",
      "source": "pubmed",
      "score": -0.66
    },
    {
      "title": "Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies.",
      "date": "2026 Apr 2",
      "source": "pubmed",
      "score": -0.66
    },
    {
      "title": "Targeted delivery of doxorubicin via cholesteryl-modified cyclodextrin: Antitumor activity in breast, ovarian, and cervical cancer cell lines.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.66
    }
  ],
  "raw_data": {
    "total_items": 102,
    "items": [
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
        "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....",
        "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html",
        "date": "2026-04-03",
        "published_at": "2026-04-03T09:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Minerva Announces Leadership Transition",
        "description": "Jim O’Connor joins as Chief Business Officer and General Counsel Jim O’Connor joins as Chief Business Officer and General Counsel",
        "url": "https://www.globenewswire.com/news-release/2026/04/02/3267830/32445/en/Minerva-Announces-Leadership-Transition.html",
        "date": "2026-04-02",
        "published_at": "2026-04-02T20:05:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Barchart.com",
        "title": "Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows",
        "description": "Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We...",
        "url": "https://www.barchart.com/story/news/1097982/buy-the-dip-these-3-over-100-stocks-just-hit-new-52-week-lows",
        "date": "2026-04-01",
        "published_at": "2026-04-01T18:51:21Z",
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook",
        "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T08:58:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
        "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T16:31:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.945,
          "confidence": 0.95
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
        "description": "Dublin, March  27, 2026  (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to  ResearchAndMarkets.com's offering.    ...",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:44:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_2499cb75-2e4c-4c25-bfe4-bcceedada92f",
        "date": "2026-03-26",
        "published_at": "2026-03-26T15:50:39Z",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "\"More Than Golf\": John Molner Reflects on the 2026 Cologuard Classic",
        "description": "While it looks like a traditional tournament on the surface, its purpose runs much deeper.",
        "url": "https://sports.yahoo.com/articles/more-golf-john-molner-reflects-204119878.html",
        "date": "2026-03-24",
        "published_at": "2026-03-24T20:41:19Z",
        "sentiment": {
          "label": "positive",
          "score": 0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "Water-extractable organic matter from tropical soils and biochar amendment tailors the colloidal behavior of nanoparticles and mitigates their toxicity through molecular eco-corona formation",
        "description": "Environ. Sci.: Nano, 2026, Advance ArticleDOI: 10.1039/D5EN01164G, PaperLaís G. Fregolente, João Vitor dos Santos, Gabriela H. Da Silva, Theodoro da R. Salles, Simone G. S. dos Santos, Luelc S. Costa, Gabriela A. Nogueira, Márcia C. Bisinoti, Carlos A. Pérez,…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/en/d5en01164g",
        "date": "2026-03-23",
        "published_at": "2026-03-23T00:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Business Insider",
        "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
        "description": "Olympic gold medalist Abby Wambach had a colonoscopy in her 30s after a family history of colon cancer. It found polyps that may have become tumors.",
        "url": "https://www.businessinsider.com/abby-wambach-colonoscopy-35-likely-saved-her-life-2026-3",
        "date": "2026-03-22",
        "published_at": "2026-03-22T13:57:46Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider",
        "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…",
        "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html",
        "date": "2026-03-17",
        "published_at": "2026-03-17T11:45:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "news",
        "source_name": "The Times of India",
        "title": "Who is Ali Larijani, ‘Kennedy of Iran’ and Iran’s top security chief, allegedly killed by Israel",
        "description": "Israel has claimed it killed Iran’s top security official Ali Larijani in recent airstrikes, a move that could reshape Tehran’s power structure. A long-time strategist and influential conservative leader, Larijani came from a powerful political dynasty once l…",
        "url": "https://economictimes.indiatimes.com/news/defence/who-is-ali-larijani-kennedy-of-iran-and-irans-top-security-chief-allegedly-killed-by-israel/articleshow/129630467.cms",
        "date": "2026-03-17",
        "published_at": "2026-03-17T10:43:20Z",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "The Times of India",
        "title": "Who is Ali Larijani, ‘Kennedy of Iran’ and Iran’s top security chief, allegedly killed by Israel",
        "description": "Israel has claimed it killed Iran’s top security official Ali Larijani in recent airstrikes, a move that could reshape Tehran’s power structure. A long-time strategist and influential conservative leader, Larijani came from a powerful political dynasty once l…",
        "url": "https://economictimes.indiatimes.com/news/new-updates/who-is-ali-larijani-kennedy-of-iran-and-irans-top-security-chief-allegedly-killed-by-israel/articleshow/129630467.cms",
        "date": "2026-03-17",
        "published_at": "2026-03-17T10:43:20Z",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "Storagereview.com",
        "title": "Everpure Aligns FlashBlade//EXA with NVIDIA AI Factory Architectures, Previews Data Stream",
        "description": "Everpure is aligning its FlashBlade//EXA platform with NVIDIA’s evolving AI Factory architectures while previewing a new automation layer called Everpure Data Stream. The announcement extends Evergreen//One support to EXA and introduces a service designed to …",
        "url": "https://www.storagereview.com/news/everpure-aligns-flashblade-exa-with-nvidia-ai-factory-architectures-previews-data-stream",
        "date": "2026-03-16",
        "published_at": "2026-03-16T20:30:04Z",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "news",
        "source_name": "USA Today",
        "title": "What to know about Cologuard Classic in Tucson on PGA Tour Champions",
        "description": "The PGA Tour Champions is back at it this week with the Cologuard Classic. Here's what you need to know ahead of the tournament in Tucson, Arizona.",
        "url": "https://golfweek.usatoday.com/story/sports/golf/champions/2026/03/16/cologuard-classic-2026-pga-tour-champions-la-paloma-preview/89121653007/",
        "date": "2026-03-16",
        "published_at": "2026-03-16T16:30:35Z",
        "sentiment": {
          "label": "positive",
          "score": 0.778,
          "confidence": 0.78
        }
      },
      {
        "source": "news",
        "source_name": "Thegatewaypundit.com",
        "title": "REPORT: As a Public School Teacher, Texas Democrat James Talarico Had Students Write ‘Obama Memoirs’ and Encouraged Them to Watch the DNC",
        "description": "Prior to getting into politics, Texas Democrat James Talarico was a middle school teacher in San Antonio.\nThe post REPORT: As a Public School Teacher, Texas Democrat James Talarico Had Students Write ‘Obama Memoirs’ and Encouraged Them to Watch the DNC appear…",
        "url": "https://www.thegatewaypundit.com/2026/03/report-as-public-school-teacher-texas-democrat-james/",
        "date": "2026-03-13",
        "published_at": "2026-03-13T03:00:55Z",
        "sentiment": {
          "label": "positive",
          "score": 0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline Value",
        "description": "This report is tailored for C-level executives, business development professionals, licensing managers, legal advisors, and anyone involved in pharmaceutical and biotechnology deal-making. It provides the tools needed to evaluate and negotiate royalty terms e…",
        "url": "https://www.globenewswire.com/news-release/2026/03/12/3254892/28124/en/Pharmaceutical-and-Biotechnology-Royalty-Rates-Agreements-Report-and-Directory-2026-Insights-Into-1-567-Licensing-Transactions-by-Company-A-Z-Therapeutic-Area-Technology-Headline-V.html",
        "date": "2026-03-12",
        "published_at": "2026-03-12T15:22:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "news",
        "source_name": "24/7 Wall St.",
        "title": "Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott",
        "description": "Citi is making a clear statement about the health of U.S. medical technology heading into the spring: the sector’s fundamentals remain intact, even as...",
        "url": "https://247wallst.com/investing/2026/03/11/intuitive-surgical-upgraded-to-buy-by-citi-plus-key-moves-on-stryker-and-abbott/",
        "date": "2026-03-11",
        "published_at": "2026-03-11T14:25:02Z",
        "sentiment": {
          "label": "positive",
          "score": 0.727,
          "confidence": 0.73
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider",
        "description": "Cell-Free DNA Testing Market to reach USD 39.43 Bn by 2035, driven by rising adoption of non-invasive prenatal screening, liquid biopsy....",
        "url": "https://www.globenewswire.com/news-release/2026/03/10/3252493/0/en/Cell-Free-DNA-cfDNA-Testing-Market-Size-to-Reach-USD-39-43-Billion-by-2035-Growth-is-Propelling-Owing-to-Continuous-Growth-of-Genomics-Research-Globally-SNS-Insider.html",
        "date": "2026-03-10",
        "published_at": "2026-03-10T09:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Global Point-of-Care Molecular Diagnostics Market Projected to Reach USD 13.05 Billion by 2035; Growth is Driven by Increasing Need for Fast Near-Patient Testing Globally – SNS Insider",
        "description": "Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Accelerating Market Expansion Globally. Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Acceler…",
        "url": "https://www.globenewswire.com/news-release/2026/03/09/3251747/0/en/Global-Point-of-Care-Molecular-Diagnostics-Market-Projected-to-Reach-USD-13-05-Billion-by-2035-Growth-is-Driven-by-Increasing-Need-for-Fast-Near-Patient-Testing-Globally-SNS-Inside.html",
        "date": "2026-03-09",
        "published_at": "2026-03-09T11:51:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXAS Technical Analysis & Stock Price Forecast",
        "url": "https://intellectia.ai/en/stock/EXAS/technical",
        "date": "2026-04-04",
        "summary": "The article provides a technical analysis for Exact Sciences Corp (EXAS), indicating a \"Strong Buy\" overall consensus based on aggregated technical signals. It details various indicators like RSI, MACD, and moving averages, along with key support and resistance levels. Despite some sell signals from momentum oscillators like RSI and Stochastic, the stock is trading above its key moving averages, suggesting a bullish trend.",
        "sentiment_score": 0.56909,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively ",
        "sentiment_score": 0.404537,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories completed its $23 billion acquisition of Exact Sciences on March 23, 2026, integrating Exact Sciences' cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics division. This acquisition positions Abbott in the growing $60 billion U.S. cancer screening market, offering North American investors exposure to diversified revenue and reduced single-product risk. Analysts view the deal positively, expecting it to be accretive long-term despite near-term EP",
        "sentiment_score": 0.005178,
        "sentiment_label": "Neutral",
        "relevance_score": 0.317708,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-stock-is-the-post-earnings-slide-a-buying-setup-for-2026/68632891",
        "date": "2026-04-03",
        "summary": "Exact Sciences stock has seen a post-earnings slide, but the company's core Cologuard franchise continues to grow, and profitability is becoming clearer. The article examines the fundamental changes, Wall Street's sentiment, and how US investors might position themselves for 2026. It highlights the company's strong revenue growth, improving margins, and robust cash position, despite ongoing unprofitability on a GAAP basis, making it a risk-reward test for high-growth healthcare investors.",
        "sentiment_score": 0.296258,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History",
        "url": "https://www.gurufocus.com/guru-portfolio/Select%20Health%20Care%20Portfolio/EXAS",
        "date": "2026-04-02",
        "summary": "This article from GuruFocus.com, titled \"Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History,\" provides historical holding information for Exact Sciences Corp (EXAS) within the Select Health Care Portfolio. The content is primarily a navigation-heavy page from a financial data website, indicating where users can find such data and related investment tools. It does not provide direct analysis or details of the holding history itself, but rather signposts the availability of s",
        "sentiment_score": 0.034312,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corps-technical-trend-changes-from-bullish-to-mildly-bullish-amid-mixed-indicators-3925987",
        "date": "2026-03-30",
        "summary": "EXACT Sciences Corp., a Pharmaceuticals & Biotechnology company, has received a mixed stock evaluation with varying technical indicators. Despite this, the company has significantly outperformed the S&P 500 over both the past year and decade, demonstrating strong resilience and stock performance recovery. Key technical indicators show both bullish and bearish signals across different timeframes.",
        "sentiment_score": 0.288195,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares",
        "url": "https://www.stocktitan.net/sec-filings/EXAS/schedule-13g-a-exact-sciences-corp-amended-passive-investment-disclos-eeadd5078360.html",
        "date": "2026-03-27",
        "summary": "The Vanguard Group has reported 0 shares of Exact Sciences (NASDAQ: EXAS) common stock, representing 0% ownership, following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing emphasizes that this reclassification is a reporting change, not an indication of a sale.",
        "sentiment_score": 0.040751,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks",
        "sentiment_score": 0.287937,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seekin",
        "sentiment_score": 0.043175,
        "sentiment_label": "Neutral",
        "relevance_score": 0.317964,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist",
        "url": "https://www.tradingview.com/news/tradingview:063a6549e37bf:0-key-facts-abbott-buys-exact-sciences-notes-settle-105-nasdaq-delist/",
        "date": "2026-03-23",
        "summary": "Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.",
        "sentiment_score": -0.431539,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott completes Exact Sciences acquisition",
        "url": "https://www.massdevice.com/abbott-completes-exact-sciences-acquisition/",
        "date": "2026-03-23",
        "summary": "Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.",
        "sentiment_score": 0.419931,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026",
        "url": "https://www.minichart.com.sg/2026/03/23/exact-sciences-corp-exas-files-8-k-announcing-material-agreements-amendments-and-supplemental-indentures-march-2026/",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.",
        "sentiment_score": 0.027063,
        "sentiment_label": "Neutral",
        "relevance_score": 0.326502,
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening",
        "url": "https://intellectia.ai/news/stock/abbott-acquires-exact-sciences-strengthening-leadership-in-cancer-screening",
        "date": "2026-03-23",
        "summary": "Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and dri",
        "sentiment_score": 0.008769,
        "sentiment_label": "Neutral",
        "relevance_score": 0.342185,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing",
        "url": "https://www.tradingview.com/news/tradingview:9f617a00194da:0-exact-sciences-announced-transfer-or-voluntary-withdrawal-of-listing/",
        "date": "2026-03-23",
        "summary": "Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.",
        "sentiment_score": -0.616464,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-analyst-scrutiny-amid-moderate-buy/68964225",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a \"Moderate Buy\" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Swi",
        "sentiment_score": 0.470932,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following",
        "date": "2026-03-21",
        "summary": "Walgreens has partnered with Exact Sciences for a nationwide rollout of the Cologuard colorectal cancer screening test through its pharmacies, which could significantly impact Exact Sciences' growth. While this expansion addresses care gaps and diversifies screening access, investors should also consider Exact Sciences' historical cash burn and dependence on Cologuard, despite new data on its Oncodetect and Cancerguard tests. The company's investment narrative projects substantial revenue and ea",
        "sentiment_score": 0.338601,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences (NASDAQ: EXAS) secures approvals as Abbott merger targets March 23 close",
        "url": "https://www.stocktitan.net/sec-filings/EXAS/8-k-exact-sciences-corp-reports-material-event-84457867e21f.html",
        "date": "2026-03-21",
        "summary": "Exact Sciences has announced that all regulatory approvals and clearances for its merger with Abbott Laboratories have been obtained. Stockholders previously approved the transaction on February 20, 2026, and the merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions. Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.",
        "sentiment_score": 0.251511,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott to close $21B Exact Sciences acquisition Monday",
        "url": "https://www.medtechdive.com/news/abbott-to-close-21b-exact-sciences-acquisition-monday/815315/",
        "date": "2026-03-20",
        "summary": "Abbott is set to finalize its $21 billion acquisition of Exact Sciences on Monday, having received all necessary regulatory clearances. This strategic move is expected to significantly bolster Abbott's presence in cancer screening and diagnostics, adding a new platform and an estimated $3 billion in incremental sales by 2026. Exact Sciences is known for its Cologuard test and other molecular cancer detection technologies, which Abbott anticipates will help reach millions more people for early ca",
        "sentiment_score": 0.496635,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences to be acquired by Abbott after receiving all regulatory approvals; closing anticipated March 23, 2026",
        "url": "https://www.tradingview.com/news/tradingview:a22546d93f58a:0-exact-sciences-to-be-acquired-by-abbott-after-receiving-all-regulatory-approvals-closing-anticipated-march-23-2026/",
        "date": "2026-03-20",
        "summary": "Exact Sciences announced that all regulatory approvals for its merger with Abbott have been received, with the transaction expected to close on March 23, 2026. This merger will make Exact Sciences a direct, wholly owned subsidiary of Abbott, following shareholder approval and regulatory clearance obtained on March 19, 2026. The closing is subject to remaining conditions and customary risks.",
        "sentiment_score": 0.443997,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Health care again among the state’s biggest M&A deals of the past year",
        "url": "https://biztimes.com/health-care-again-among-the-states-biggest-ma-deals-of-the-past-year/?amp=1",
        "date": "2026-03-18",
        "summary": "For the third consecutive year, a healthcare-focused company deal is among Wisconsin's largest mergers and acquisitions. Exact Sciences, based in Madison, was acquired by Illinois-based Abbott Laboratories for $21 billion in November. This acquisition follows other significant healthcare M&A deals in the state and notable acquisitions by Modine and several other Wisconsin-based companies across various sectors.",
        "sentiment_score": 0.416858,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Hits New 52-Week High at $104.00",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10400-3899129",
        "date": "2026-03-18",
        "summary": "EXACT Sciences Corp. (EXAS) has achieved a new 52-week high of $104.00, marking a significant 142.34% appreciation over the past year, far outpacing the S&P 500. The company, a mid-cap player in pharmaceuticals and biotechnology with a market capitalization of $19.8 billion, shows a manageable debt-to-equity ratio despite being a loss-making entity with a negative return on equity. This price movement highlights strong investor sentiment and dynamic market activity for the stock.",
        "sentiment_score": 0.453591,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026",
        "url": "https://www.businesswire.com/news/home/20260317158639/en/Exact-Sciences-to-Present-New-Molecular-Residual-Disease-and-Multi-Cancer-Early-Detection-Data-at-AACR-2026",
        "date": "2026-03-17",
        "summary": "Exact Sciences Corp. announced it will present new data on molecular residual disease (MRD) testing and multi-cancer early detection (MCED) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight findings from the Oncodetect® test in triple-negative breast cancer and updated performance for the Cancerguard® test, reinforcing the company's strategy to detect cancer earlier and monitor disease post-treatment. These results showcase advancements ",
        "sentiment_score": 0.406438,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Hits New 52-Week High at $103.92",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10392-3897175",
        "date": "2026-03-17",
        "summary": "EXACT Sciences Corp. reached a new 52-week high of $103.92, demonstrating strong performance in the Pharmaceuticals & Biotechnology sector with a 142.13% stock price increase over the last year. Despite being a loss-making entity, the company maintains a manageable debt-to-equity ratio of 0.58 and a market capitalization of approximately $19.74 billion, with investors focusing on capital appreciation due to no dividend yield.",
        "sentiment_score": 0.415698,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval",
        "url": "https://www.msn.com/en-us/money/markets/exact-sciences-exas-merger-with-abbott-moving-forward-after-shareholder-approval/ar-AA1Xe0H5?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-17",
        "summary": "This article reports on the merger between Exact Sciences (EXAS) and Abbott (ABT) moving forward after Exact Sciences shareholders approved the deal. The acquisition will allow Exact Sciences to expand its cancer diagnostic products into new markets and leverage Abbott's global presence. The approval marks a significant step towards the completion of the merger.",
        "sentiment_score": 0.497471,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Jain Global LLC Purchases Shares of 481,607 Exact Sciences Corporation $EXAS",
        "url": "https://www.marketbeat.com/instant-alerts/filing-jain-global-llc-purchases-shares-of-481607-exact-sciences-corporation-exas-2026-03-16/",
        "date": "2026-03-16",
        "summary": "Jain Global LLC has acquired a significant new position in Exact Sciences (NASDAQ:EXAS), purchasing 481,607 shares valued at approximately $26.35 million. Other institutional investors like Holocene Advisors and Fred Alger Management also increased their stakes, bringing total institutional ownership to about 88.82%. Despite the increased institutional interest, analysts maintain a cautious outlook, with an average \"Reduce\" rating and a consensus target price of $92.13, even as the stock trades ",
        "sentiment_score": -0.205715,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp Stock (ISIN: US30063P1057) Attracts Major Investors Amid Cancer Screening Moment",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-isin-us30063p1057-attracts-major-investors/68686842",
        "date": "2026-03-15",
        "summary": "Exact Sciences Corp. (EXAS) is attracting significant institutional investment, with firms like Bamco Inc. NY increasing their stakes, signaling strong confidence in its colorectal cancer screening leadership. Despite broader healthcare sector pressures and economic uncertainties, investors are drawn to the company's growth trajectory, its flagship Cologuard test, and its potential in preventive oncology, positioning EXAS for a potential rebound. European and DACH region investors are also showi",
        "sentiment_score": 0.445592,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.452,
          "confidence": 0.45
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp.",
        "url": "https://www.marketbeat.com/instant-alerts/filing-exact-sciences-corporation-exas-shares-purchased-by-efg-asset-management-americas-corp-2026-03-15/",
        "date": "2026-03-15",
        "summary": "EFG Asset Management Americas Corp. significantly increased its stake in Exact Sciences (NASDAQ:EXAS) by 60% in Q3, acquiring 13,910 additional shares, bringing its total to 37,109 shares valued at approximately $2.03 million. This increase in institutional ownership comes despite several analysts recently downgrading EXAS to \"Hold\" or \"Neutral,\" with an average \"Reduce\" rating and a target price of $92.13. The company also missed quarterly EPS expectations, reporting $(0.21) against a $0.08 est",
        "sentiment_score": -0.220783,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval",
        "url": "http://www.msn.com/en-us/money/markets/exact-sciences-exas-merger-with-abbott-moving-forward-after-shareholder-approval/ar-AA1Xe0H5?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-15",
        "summary": "The article reports that the proposed merger between Exact Sciences (EXAS) and Abbott is progressing well, following key approval from shareholders. This development signifies a major step towards the completion of the acquisition, indicating that the deal is on track to close as planned.",
        "sentiment_score": 0.425357,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Privia Health Screening Program Increases Colorectal Cancer Screening Rates",
        "url": "https://www.mychesco.com/a/news/regional/privia-health-screening-program-increases-colorectal-cancer-screening-rates/",
        "date": "2026-03-14",
        "summary": "Privia Health, in collaboration with Amalgam Rx Inc. and Exact Sciences Corp., successfully increased colorectal cancer screening rates to 84% in 2024 through a program integrating electronic health record workflows and automated patient outreach. The initiative, which utilized Exact Sciences’ Cologuard test, engaged over 100,000 patients nationally and identified more than 550 individuals requiring diagnostic follow-up. This program demonstrates the effectiveness of technology in proactive prev",
        "sentiment_score": 0.400614,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Mackenzie Financial Corp Has $150.11 Million Stake in Exact Sciences Corporation $EXAS",
        "url": "https://www.marketbeat.com/instant-alerts/filing-mackenzie-financial-corp-has-15011-million-stake-in-exact-sciences-corporation-exas-2026-03-12/",
        "date": "2026-03-12",
        "summary": "Mackenzie Financial Corp recently decreased its stake in Exact Sciences Corporation by 3.9%, now holding 2,743,819 shares valued at $150.11 million. Several other institutional investors have also adjusted their holdings. Analysts currently have a \"Reduce\" consensus rating for Exact Sciences, with an average target price of $92.13, despite the company missing its last quarterly EPS estimates while revenue grew by 23.1%.",
        "sentiment_score": -0.212516,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41942914",
        "title": "Social needs screening in hepatology clinic: a qualitative study of patient experience.",
        "authors": "Kim RG et al.",
        "journal": "BMC gastroenterology",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41942914/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41941938",
        "title": "Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.",
        "authors": "Becherini C et al.",
        "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "date": "2026 Apr 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41941938/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41935709",
        "title": "Learning to breathe for radiation therapy: a scoping review of deep inspiration breath-hold training.",
        "authors": "Lastrucci A et al.",
        "journal": "Critical reviews in oncology/hematology",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41935709/",
        "sentiment": {
          "label": "positive",
          "score": 0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41935304",
        "title": "From healing landscapes to biocultural conservation: the role of Ficus septica in karst ecosystems of South Sulawesi, Indonesia.",
        "authors": "Ismail A et al.",
        "journal": "Journal of ethnobiology and ethnomedicine",
        "date": "2026 Apr 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41935304/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41934720",
        "title": "Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates.",
        "authors": "Thill M et al.",
        "journal": "Breast (Edinburgh, Scotland)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41934720/",
        "sentiment": {
          "label": "negative",
          "score": -0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "pubmed",
        "pmid": "41933521",
        "title": "Mind-wandering facilitates creative performance in a musical improvisation task.",
        "authors": "Palhares PT et al.",
        "journal": "Consciousness and cognition",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41933521/",
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "pubmed",
        "pmid": "41932199",
        "title": "Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies.",
        "authors": "Cescon E et al.",
        "journal": "Clinical breast cancer",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41932199/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41931881",
        "title": "Effect of folic acid supplemented feed on metabolic and redox balance, and sperm movement in silver catfish (Rhamdia quelen) males.",
        "authors": "Baumgartner LA et al.",
        "journal": "Theriogenology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41931881/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41931218",
        "title": "Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.",
        "authors": "Del Re M et al.",
        "journal": "Drugs",
        "date": "2026 Apr 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41931218/",
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "pubmed",
        "pmid": "41930153",
        "title": "The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes.",
        "authors": "Dalbeni A et al.",
        "journal": "Oncology research",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41930153/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41929668",
        "title": "Clinical Characteristics and Severity of Rhinovirus/Enterovirus-Associated Hospitalizations: A Multicountry Analysis From the Global Influenza Hospital Surveillance Network, 2017-2024.",
        "authors": "Revilla AM et al.",
        "journal": "Open forum infectious diseases",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41929668/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41928668",
        "title": "Green-synthesized Titanium Dioxide Nanoparticles: Systematic Review of Antimicrobial Efficacy and Biocompatibility.",
        "authors": "R Silva G et al.",
        "journal": "Mini reviews in medicinal chemistry",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41928668/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41927568",
        "title": "Tensorial quantum mechanics.",
        "authors": "de Ronde C et al.",
        "journal": "Scientific reports",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41927568/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41925922",
        "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.",
        "authors": "Hörner M et al.",
        "journal": "Breast cancer research and treatment",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41922546",
        "title": "Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).",
        "authors": "Gupta S et al.",
        "journal": "Prostate cancer and prostatic diseases",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41922546/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41921193",
        "title": "Risk-stratified surveillance for hepatocellular carcinoma.",
        "authors": "Hunold T et al.",
        "journal": "Hepatology communications",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41921193/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41920280",
        "title": "Data-Driven Bioprocess Optimization: Lipase Production by Aspergillus Niger ATCC 1004 in COCOA and Palm Oil Byproducts Based Solid State Fermentation.",
        "authors": "do Espirito Santo EL et al.",
        "journal": "Applied biochemistry and biotechnology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41920280/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41918407",
        "title": "Insights Into Antivirulence Applications of Macrochloa tenacissima (L.) Kunth (Poaceae) From In Vitro and In Silico Assessments.",
        "authors": "Houam A et al.",
        "journal": "Chemistry & biodiversity",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41918407/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41917040",
        "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.",
        "authors": "Liang J et al.",
        "journal": "Nature communications",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/",
        "sentiment": {
          "label": "negative",
          "score": -1.0,
          "confidence": 1.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41916246",
        "title": "Temperature effects on oxidative, phenolic and osmoprotective traits in lingonberry (Vaccinium vitis-idaea L.) fruits from contrasting provenances.",
        "authors": "Aparaschive CM et al.",
        "journal": "Journal of environmental management",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41916246/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41915379",
        "title": "Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.",
        "authors": "Ortendahl JD et al.",
        "journal": "Journal of medical economics",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41915379/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41912809",
        "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.",
        "authors": "Wainberg ZA et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41911435",
        "title": "Digital Intervention (MiVacunaLA 2.0) to Promote COVID-19 Vaccine Acceptance Among Hispanic Children: Community-Based Randomized Controlled Trial.",
        "authors": "Blanco LR et al.",
        "journal": "Journal of medical Internet research",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41911435/",
        "sentiment": {
          "label": "positive",
          "score": 0.681,
          "confidence": 0.68
        }
      },
      {
        "source": "pubmed",
        "pmid": "41910935",
        "title": "Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.",
        "authors": "Schreiber S et al.",
        "journal": "Advances in therapy",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41910935/",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "pubmed",
        "pmid": "41908680",
        "title": "Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.",
        "authors": "Jairath V et al.",
        "journal": "Crohn's & colitis 360",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41908680/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41906627",
        "title": "Schwann Cell TRPA1, a Proalgesic Ion Channel, Mediates Neuroinflammation and Fibromyalgia-Associated Behaviours in Mice.",
        "authors": "Brum ES et al.",
        "journal": "Journal of neurochemistry",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41906627/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41906483",
        "title": "Parasites of two populations of Psalidodon bifasciatus (Characiformes): Enemy release suggesting introduction of hosts in Neotropical streams.",
        "authors": "Miguel BS et al.",
        "journal": "Journal of helminthology",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41906483/",
        "sentiment": {
          "label": "negative",
          "score": -0.542,
          "confidence": 0.54
        }
      },
      {
        "source": "pubmed",
        "pmid": "41906026",
        "title": "Correction to: Bacterial microbiota dynamics of Cannabis sativa L. under biotic stress induced by Tetranychus urticae.",
        "authors": "Pinto Alman L et al.",
        "journal": "Protoplasma",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41906026/",
        "sentiment": {
          "label": "negative",
          "score": -0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "pubmed",
        "pmid": "41906000",
        "title": "Touch and manual action in chemotherapy-induced peripheral neuropathy: a mixed-methods study.",
        "authors": "Roberts RD et al.",
        "journal": "Scientific reports",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41906000/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41903996",
        "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.",
        "authors": "Teixeira MF et al.",
        "journal": "Surgical oncology clinics of North America",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "41903664",
        "title": "Targeted delivery of doxorubicin via cholesteryl-modified cyclodextrin: Antitumor activity in breast, ovarian, and cervical cancer cell lines.",
        "authors": "Maliszewski B et al.",
        "journal": "Chemico-biological interactions",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41903664/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41902784",
        "title": "Real-world adherence to multi-target stool DNA testing and its association with time to follow-up colonoscopy: a health-system analysis from Massachusetts General Hospital.",
        "authors": "Greene M et al.",
        "journal": "Current medical research and opinion",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41902784/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41901635",
        "title": "Recent Developments and Applicability of In Vitro Gut Microbiota Models in Biomedical Research and Digestive Diseases-A Systematic Review.",
        "authors": "Balmus IM et al.",
        "journal": "Medicina (Kaunas, Lithuania)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41901635/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41901051",
        "title": "Correction: Hernández-Fuentes et al. Moringa oleifera Leaf Infusion as a Functional Beverage: Polyphenol Content, Antioxidant Capacity, and Its Potential Role in the Prevention of Metabolopathies. Life 2025, 15, 636.",
        "authors": "Hernández-Fuentes GA et al.",
        "journal": "Life (Basel, Switzerland)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41901051/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41900458",
        "title": "Phenotypic and Metabolic Variations in High-Risk Clones of Multidrug-Resistant Pseudomonas aeruginosa.",
        "authors": "Gutierrez SJ et al.",
        "journal": "Microorganisms",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41900458/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41899536",
        "title": "Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer.",
        "authors": "Yamamoto Y",
        "journal": "Cancers",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41899536/",
        "sentiment": {
          "label": "negative",
          "score": -0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "pubmed",
        "pmid": "41899531",
        "title": "Association Between Single-Nucleotide Polymorphism and Trastuzumab Deruxtecan-Induced Interstitial Lung Disease in Breast Cancer Using the Japonica Array NEO.",
        "authors": "Fujiwara S et al.",
        "journal": "Cancers",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41899531/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41898701",
        "title": "7-Ketocholesterol Links Sterol Homeostasis to Hedgehog Signaling and Stress-Survival Responses in MSCs from Patients with Acute Myeloid Leukemia.",
        "authors": "Reichert CO et al.",
        "journal": "International journal of molecular sciences",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41898701/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41898529",
        "title": "Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.",
        "authors": "Thu KL et al.",
        "journal": "International journal of molecular sciences",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41898529/",
        "sentiment": {
          "label": "negative",
          "score": -0.691,
          "confidence": 0.69
        }
      },
      {
        "source": "pubmed",
        "pmid": "41895663",
        "title": "Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosis.",
        "authors": "Patel A et al.",
        "journal": "JHEP reports : innovation in hepatology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41895663/",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "pubmed",
        "pmid": "41887238",
        "title": "Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis.",
        "authors": "Younossi ZM et al.",
        "journal": "The lancet. Gastroenterology & hepatology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41887238/",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "pubmed",
        "pmid": "41886167",
        "title": "Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).",
        "authors": "Watanuki R et al.",
        "journal": "Breast cancer (Tokyo, Japan)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41886167/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41886058",
        "title": "Nanocarrier-mediated delivery of polyphenols: an emerging strategy for overcoming biological barriers in gastrointestinal cancer therapy.",
        "authors": "Vijayakumar S et al.",
        "journal": "Bioprocess and biosystems engineering",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41886058/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41885821",
        "title": "Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.",
        "authors": "Mavromatis LA et al.",
        "journal": "JAMA oncology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41885821/",
        "sentiment": {
          "label": "negative",
          "score": -0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "pubmed",
        "pmid": "41883872",
        "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.",
        "authors": "Qadri F et al.",
        "journal": "Therapeutic advances in medical oncology",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41879223",
        "title": "Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.",
        "authors": "Dore M et al.",
        "journal": "Journal of medical economics",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41879223/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41878007",
        "title": "Genetic constraints on protein loop evolution: out-of-frame stop codons limit Bacillus subtilis stationary-phase mutagenesis.",
        "authors": "Vallin C et al.",
        "journal": "Frontiers in molecular biosciences",
        "date": "2026-04-07",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41878007/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41877310",
        "title": "Zero-Dalton Resolution in Nanopore Peptide Recognition.",
        "authors": "Afshar Bakshloo M et al.",
        "journal": "Analytical chemistry",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41877310/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41876939",
        "title": "Diosmetin as an Effective Treatment for Cisplatin-Induced Neuropathic Pain in Mice which does not Cause Hepatic or Renal Biomarker Alterations.",
        "authors": "Serafini PT et al.",
        "journal": "Molecular neurobiology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41876939/",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "pubmed",
        "pmid": "41867572",
        "title": "Natural Maghemite Nanoparticles in Crude Oil Seen by Electron Paramagnetic Resonance.",
        "authors": "Pessoa MS et al.",
        "journal": "ACS omega",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41867572/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-23",
        "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-20",
        "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526116862/0001193125-26-116862-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}